

ANZGOG Preceptorship in Targeting Molecular Pathways in Gynae Cancer
DAY 1 – Friday, 29 November | 1.00pm – 4.00pm AEDT



1.00pm – 1.05pm	WELCOME – <i>Anna DeFazio AM and George Au-Yeung</i>	
1.05pm – 1.20pm	How to get involved with ANZGOG clinical trials – mentoring new researchers. – <i>John Andrews, ANZGOG Research Manager</i> 5 min Q&A	
1.20pm – 1.30pm	ANZGOG Community Research Engagement Program – <i>Speaker TBC</i>	
1.30pm – 2.30pm	Mentors	LOW-GRADE SEROUS OVARIAN CANCER AND SYNCHRONOUS OVARY/ENDOMETRIAL CANCERS
	Lyndal Anderson	What are the defining molecular and histopathological characteristics that differentiate low-grade from high-grade serous ovarian carcinoma? Can low-grade serous ovarian cancer become high-grade? Asmerom Segal 2.5 mins Q&A
	Heather Cunliffe	What are the predominant oncogenic gene mutations associated with low-grade serous ovarian carcinoma and what have been the outcomes of clinical trials targeting these alterations? Wai-Hoong Chan 2.5 mins Q&A
	Cristina Mapagu	Concurrent carcinoma involving the endometrium and ovary – what is the molecular evidence against/for these neoplasms being independent primary ‘synchronous’ tumours? What are the challenges and current clinical guidelines for assigning stage in these cases? Catherine Schepisi 2.5 mins Q&A
	Gwo-Yaw Ho	Outside of endometrial cancer, which gynaecological cancers have shown response to immune checkpoint inhibitors and are there molecular features associated with response? Laura Sunderland 2.5 mins Q&A
	10 mins	Preceptor Panel Discussion
2.30pm – 3.20pm	Kylie Gorringe	RARE OVARIAN HISTOTYPES What are the predominant molecular alterations in mucinous ovarian cancer? What are the current treatment recommendations, therapeutic opportunities and challenges for clinical trials in patients with mucinous ovarian cancer? Nicla Varneir-Liu 2.5 mins Q&A
	Alicia Didsbury	What are the predominant molecular alterations in clear cell ovarian cancer? What are the clinical characteristics, therapeutic opportunities, recent and on-going clinical trials in clear cell ovarian cancer? Marta Preston 2.5 mins Q&A

	Linda Mileskin	What are the predominant molecular alterations in endometrioid ovarian cancer? Are there any therapeutic opportunities to be explored? Harrison Odgers 2.5 mins Q&A
	10 mins	Preceptor Panel Discussion
3.20pm – 3.30pm	10 mins	Break
3.30pm – 4.05pm	Jeffrey Goh Michelle Harrison	CERVIX AND GYNAE SARCOMAS What are the systemic options for the Rx of non-HPV driven locally advanced and recurrent/metastatic cervical cancers. List your Rx options according to the variant histologies. Mandy Wang 2.5 mins Q&A Outline the uterine sarcomas with reference to leiomyosarcoma, high and low-grade sarcoma, stromal sarcomas and ultra-rare sarcomas. What do we know of the molecular landscape of these rare tumours? How may we exploit these finding for future treatment opportunities? Cheryl Yim 2.5 mins Q&A
	10 mins	Preceptor Panel Discussion
4.05pm		CLOSING –Anna DeFazio AM & George Au-Yeung

Day 2 – Saturday, 30 November 10.00am – 12.30pm AEDT		
10.00am – 10.05am	WELCOME – <i>Anna DeFazio AM & George Au-Yeung</i>	
10.05am – 10.55am	Nikki Burdett	MOLECULAR TESTING IN HIGH-GRADE SEROUS OVARIAN CANCER What are the current recommendations for somatic and germline testing in patients with newly diagnosed high-grade serous ovarian cancer? Caoimhe O'Sullivan 2.5 mins Q&A
	Nikki Burdett	What is homologous recombination DNA repair deficiency? How is it relevant to the management of gynaecologic cancer? Conor Hayton 2.5 mins Q&A
	Gwo-Yaw Ho	What are the molecular subtypes of high-grade serous ovarian cancer? How are they identified? What have been the challenges in clinical implementation of this classification? Charmian Eng 2.5 mins Q&A
	10 mins	Preceptor Panel Discussion
10.55am – 11.30am	Yoland Antill	MOLECULAR PROFILING IN ENDOMETRIAL CANCER What are the molecular subtypes of endometrial cancer? How is the molecular subtype of a case of endometrial cancer determined? Are there treatment recommendations that can be made based on the molecular subtypes of endometrial cancer? Sita Murugappan 2.5 mins Q&A
	Yoland Antill	What is Lynch syndrome? Which patients with gynae-cancer should be screened for Lynch syndrome and what are the clinical implications? Helena Obermair 2.5 mins Q&A
	10 mins	Preceptor Panel Discussion
11.30am – 12.30am	Kate Webber	EMERGING TARGETS IN GYNAE CANCER Mirvetuximab soravtansine, targeting folate receptor alpha (FR α , FOLR1) has been granted accelerated approval in the USA for platinum-resistant ovarian carcinoma. What is the expression of FOLR1 across histological subtypes and summarise the clinical trial evidence for this treatment in ovarian carcinoma to date. Erin Pearson 2.5 mins Q&A

	<p>Kylie Gorringe</p>	<p>Antibody Drug Conjugates (ADCs) targeting HER2 have been rapidly adopted as standard-of-care for advanced breast cancer following demonstration of significant survival benefit. What is known about expression of HER2 in histological subtypes of Gyn cancers? Sarah Ingamells</p> <p style="text-align: right;">2.5 mins Q&A</p>
	<p>Rosemary Balleine</p>	<p>What is the frequency of POLE mutations in endometrial cancer? What are the clinical associations and potential treatment implications. Morgan Eckermann</p> <p style="text-align: right;">2.5 mins Q&A</p>
	<p>Liz Christie</p>	<p>What are 'reversion mutations'? How are reversion mutations in <i>BRCA1/2</i> relevant to treatment of high-grade serous ovarian cancer? Zoe Phan</p> <p style="text-align: right;">2.5 mins Q&A</p>
	<p>10 mins</p>	<p>Preceptor Panel Discussion</p>
<p>12.30pm</p>		<p>CLOSING - <i>Anna DeFazio AM & George Au-Yeung</i></p>